Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 375 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombocytopenia Clear all
Completed Phase 1 Interventional

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

NCT02948283
View directory record Official record
Conditions
Anemia, Fatigue, Fever, Lymphadenopathy, Lymphocytosis, Night Sweats, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 11, 2026, 5:05 AM EDT
Withdrawn Phase 4 Interventional

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

NCT00759083
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

NCT05325346
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
VLX-1005, Argatroban
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

NCT03395210
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Rilzabrutinib
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Peoria, Illinois • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 11, 2026, 5:05 AM EDT
Completed No phase listed Observational

Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia

NCT06824727
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Baseline cell blood counts
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Withdrawn Phase 2 Interventional

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

NCT05509582
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Romiplostim, healthy controls
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 11, 2026, 5:05 AM EDT
Withdrawn Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415
View directory record Official record
Conditions
Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Interventions
HMPL-523
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Avatrombopag vs. Placebo for CIT in GI Malignancies

NCT05772546
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions
Avatrombopag, Matching Placebo
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 11, 2026, 5:05 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798
View directory record Official record
Conditions
Chronic Immune Thrombocytopenia
Interventions
Panzyga
Biological
Lead sponsor
Octapharma
Industry
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Sacramento, California • Minneapolis, Minnesota • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 11, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

NCT04671901
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Withdrawn No phase listed Observational

The Role of Microparticles as a Biomarker

NCT02626663
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 11, 2026, 5:05 AM EDT
Completed No phase listed Observational

Association of Platelet Parameters With Bleeding Severity in Children With ITP

NCT03810352
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 20 Years
Enrollment
95 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

NCT00358540
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Santa Monica, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

NCT00913133
View directory record Official record
Conditions
Thrombosis
Interventions
Desirudin
Drug
Lead sponsor
Canyon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
16
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 11, 2026, 5:05 AM EDT
Completed No phase listed Observational

Registry for Vascular Anomalies Associated With Coagulopathy

NCT00576888
View directory record Official record
Conditions
Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Cutaneovisceral Angiomatosis With Thrombocytopenia, Vascular Anomaly With Thrombocytopenia, Hemangiomas
Interventions
no intervention
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 11, 2026, 5:05 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

NCT03205995
View directory record Official record
Conditions
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 11, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

NCT00706342
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Fostamatinib Disodium / R935788
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 11, 2026, 5:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag, Azacitidine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 11, 2026, 5:05 AM EDT
Recruiting No phase listed Observational

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

NCT06817395
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 11, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

NCT00413114
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Obatoclax mesylate (GX15-070MS)
Drug
Lead sponsor
Gemin X
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 11, 2026, 5:05 AM EDT